Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and GIP , may represent a significant development for obesity management . Preliminary human trials have shown substantial losses in abdominal tissue, conceivably surpassing existing obesity therapies . However , further study is needed to fully determine its sustained effica